Journal: Pharmaceuticals

Article Title: New Genetic Bomb Trigger: Design, Synthesis, Molecular Dynamics Simulation, and Biological Evaluation of Novel BIBR1532-Related Analogs Targeting Telomerase against Non-Small Cell Lung Cancer

doi: 10.3390/ph15040481

Figure Lengend Snippet: Telomerase activity in cancer cells as a percent of control cells with target compounds 29a , 36b , and 39b .

Article Snippet: The human A549 (epithelial cell lung carcinoma, ATCC, Manassas, VA, USA), HCC44 (non-small cell lung adenocarcinoma, Leibniz Institute DSMZ-German Collection of the Microorganisms and the Cell Cultures, Braunschweig, Germany), and NCI-H23 (non-small cell lung adenocarcinoma, ATCC, Manassas, VA, USA) cell lines (compounds 29a , 36b , and 39b ) were diluted to 10 μM and incubated for 48 h before being tested using the TRAP method.

Techniques: Activity Assay, Control

Journal: Cell reports

Article Title: Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer.

doi: 10.1016/j.celrep.2019.12.056

Figure Lengend Snippet: Figure 7. EZH2 Inhibition Impairs Metastasis in TNBC Subtype-Specific PDX Models (A) EZH2 and GATA3 expression of the METABRIC dataset of 347 breast cancer patients, available in cBioportal and grouped by Pietenpol TNBC subtypes. Data represent median ± interquartile range (Wilcox t test). (B) Quantitative analysis of the invasive potential of HCC1937 (BL-1), MDA-MB-468 (BL-1), BT-549 (M), CAL-120 (M), MDA-MB-453 (LAR), SUM185 (LAR), and CAL-148 (LAR) cell lines following treatment with vehicle or drug (5 mM GSK-126 for 5 days) and quantification of invasive cells of six distinct images in each replicate (n = 3) per group. The invasion of vehicle-treated cells was set at 1.

Article Snippet: Human breast cell lines MCF10A, MDA-MB-361, MCF7, MDA-MB-436, MDA-MB-231, BT-20, HCC1937, HCC1395, MDA-MB-468, DU4475, BT-549, SUM-159, CAL-120, CAL-148, MDA-MB-453 and SUM-185 were obtained from ATCC (Manassas, VA, USA) and DSMZ (Germany).

Techniques: Inhibition, Expressing

Journal: Evidence-based Complementary and Alternative Medicine : eCAM

Article Title: Evaluation of Preclinical Assays to Investigate an Anthroposophic Pharmaceutical Process Applied to Mistletoe ( Viscum album L.) Extracts

doi: 10.1155/2014/620974

Figure Lengend Snippet: Comparison of ED50 [ μ g/mL] values of Viscum album extract (VAE) Mali and anthroposophically processed Viscum album extract (APVAE) Mali in five different cell lines. Mean ± SD based on 8 independent experiments each. 4th column: APVAE ED50 values expressed relative to VAE data set to 100%. 5th column: t -test for independent samples.

Article Snippet: The human carcinoma cell lines HCC1143 (breast carcinoma), PA-TU-8902 (pancreas adenocarcinoma), DU-145 (prostate carcinoma), and NCI-H460 (lung carcinoma) were obtained from the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures (Germany).

Techniques: Comparison

Journal: Epigenetics

Article Title: Suppressing circIDE/miR-19b-3p/RBMS1 axis exhibits promoting-tumour activity through upregulating GPX4 to diminish ferroptosis in hepatocellular carcinoma

doi: 10.1080/15592294.2023.2192438

Figure Lengend Snippet: RBMS1 is downregulated in HCC and low expression of RBMS1 correlates with poor HCC patient survival. (a) RT-qPCR analysis of RBMS1 expression in 25 cases paired HCC tissues and adjacent liver tissues. (b) Comparison of RBMS1 expression between patients with T stage 1–2 (T1+T2, n =25) and T stage 3–4 (T3+T4, n =12), detected by RT-qPCR. (c) Comparison of RBMS1 expression between patients with TNM stage I-II ( n =23) and TNM stage III-IV ( n =14), detected by RT-qPCR. (d) Western blotting analysis of RBMS1 expression in HCC tissues and normal liver tissues. ( e, f) Representative images and statistics of IHC staining of RBMS1 in HCC tissue of T stage T1 and T3 and clinical TNM stage I and III. Scale bar, 50 µm. (g) Kaplan–Meier analysis of correlation between RBMS1 expression and OS, RFS. (h) Forrest plot of univariate or multivariate Cox proportional hazard regression indicated the impact of different characteristics on OS and RFS. Data are denoted as mean ± SD from three independent experiments.

Article Snippet: Blocking the sections in PBS with 5% BSA for 25 min at room temperature and then incubating the sections with antibodies specific for RBMS1 (1:100, Cat#11061–2-AP, Proteintech), GPX4 (1:200, Cat#A1933, ABclonal), 4HNE (1:100, Cat#MBS808701), and Ki67 (1:100, Cat#16667, Abcam) overnight.

Techniques: Expressing, Quantitative RT-PCR, Comparison, Western Blot, Immunohistochemistry

Journal: Epigenetics

Article Title: Suppressing circIDE/miR-19b-3p/RBMS1 axis exhibits promoting-tumour activity through upregulating GPX4 to diminish ferroptosis in hepatocellular carcinoma

doi: 10.1080/15592294.2023.2192438

Figure Lengend Snippet: RBMS1 overexpression promotes ferroptosis in HCC cells. (a) RT-qPCR analysis for the expression of RBMS1 in normal liver cell line and HCC cell lines. (b) RT-qPCR analysis of efficiency of RBMS1 overexpression in HepG2 and Hep3B cell lines, compared to empty vector. (c) Western blotting of analysis of RBMS1, GPX4, and SLC7A11 expression in HepG2 and Hep3B as indicated treatments. (d) Half-life of GPX4 mRNA after treatment with ActD in HepG2 and Hep3B cells with or without RBMS1 overexpression. (e) Schematic of GPX4 luciferase reporter plasmids. GPX4-RLuc-FL (the full length of 3’-UTR); GPX4-RLuc-D1 (1–69 nt region of 3’UTR); and GPX4-RLuc-D2 (70–139 nt region of 3’UTR). (f-g) The relative luciferase activity of HepG2 and Hep3B cells with or without RBMS1 overexpression after transfecting GPX4-RLuc-FL (f) , GPX4-RLuc-D1, and GPX4-RLuc-D2 (g) luciferase reporter vectors. (h) Representative images of H2DCFDA staining (green) and quantification of ROS level in HepG2 and Hep3B cells. Scale bar, 5 µm. (i) The assessment of MDA level in HepG2 and Hep3B cells. (j) Relative cell viability of HepG2 and Hep3B cells with or without RBMS1 overexpression after treated with erastin, ferrostatin-1, or both combined compared to corresponding control group. (k) Immunohistochemistry staining and correlation analysis of protein levels of RBMS1, GPX4, and 4HNE in clinical HCC samples. Scale bar, 50 µm. Data are denoted as mean ± SD from three independent experiments.

Article Snippet: Blocking the sections in PBS with 5% BSA for 25 min at room temperature and then incubating the sections with antibodies specific for RBMS1 (1:100, Cat#11061–2-AP, Proteintech), GPX4 (1:200, Cat#A1933, ABclonal), 4HNE (1:100, Cat#MBS808701), and Ki67 (1:100, Cat#16667, Abcam) overnight.

Techniques: Over Expression, Quantitative RT-PCR, Expressing, Plasmid Preparation, Western Blot, Luciferase, Activity Assay, Staining, Control, Immunohistochemistry

Journal: Epigenetics

Article Title: Suppressing circIDE/miR-19b-3p/RBMS1 axis exhibits promoting-tumour activity through upregulating GPX4 to diminish ferroptosis in hepatocellular carcinoma

doi: 10.1080/15592294.2023.2192438

Figure Lengend Snippet: GPX4 rescues the inhibiting proliferation effect of HCC cells induced by RBMS1 overexpression in vitro and in vivo . (a) Western blotting analysis of RBMS1 and GPX4 expression in RBMS1-overexpressed HepG2 and Hep3B cells with or without GPX4 overexpression, compared to vector control. (b-d) Effects of RBMS1 overexpression with or without GPX4 overexpression on the proliferation of HepG2 and Hep3B cells were, respectively, assessed by CCK-8 assay (b) , colony formation assay (c), and EdU staining (d) , scale bar, 20 µm. (e-g) Hepa 1–6 cells (transduced with empty vector lentivirus, or vector overexpressing RBMS1 withor without overexpressing GPX4) were subcutaneously injected into the right flank of C57BL/6 mice. RT-qPCR analysis for the expression of RBMS1 and GXP4 in Hepa 1–6 cells (e) . Tumor growth was monitored by Xenogen IVIS 200 imaging system (f) . Western blotting analysis for the expression of RBMS1, GPX4, and 4HNE in Hepa 1–6 cells (g) . Data are denoted as mean ± SD from three independent experiments.

Article Snippet: Blocking the sections in PBS with 5% BSA for 25 min at room temperature and then incubating the sections with antibodies specific for RBMS1 (1:100, Cat#11061–2-AP, Proteintech), GPX4 (1:200, Cat#A1933, ABclonal), 4HNE (1:100, Cat#MBS808701), and Ki67 (1:100, Cat#16667, Abcam) overnight.

Techniques: Over Expression, In Vitro, In Vivo, Western Blot, Expressing, Plasmid Preparation, Control, CCK-8 Assay, Colony Assay, Staining, Transduction, Injection, Quantitative RT-PCR, Imaging

Journal: Epigenetics

Article Title: Suppressing circIDE/miR-19b-3p/RBMS1 axis exhibits promoting-tumour activity through upregulating GPX4 to diminish ferroptosis in hepatocellular carcinoma

doi: 10.1080/15592294.2023.2192438

Figure Lengend Snippet: MiR-19b-3p inhibits ferroptosis and potentiates proliferation of HCC cells by repressing RBMS1 expression. (a) Prediction of miRNAs targeting RBMS1 by miRmap, PicTar, TargetScan, and PITA databases. (b) The expression of miR-19a-3p, miR-19b-3p, miR-124-3p, miR-129-5p, miR-376-3p, miR-383-5p, miR-487a-3p, and miR-501-3p in HCC and normal liver tissues through TCGA database. (c, d) RT-qPCR and western blotting analysis for the expression of RBMS1 in HepG2 and Hep3B cells after transfecting miR-19b-3p inhibitor. (e) Schematic diagram of luciferase reporter vector containing wild-type (WT) or mutant (MUT) putative miR-19b-3p binding sites of the 3’ UTR of RBMS1. (f) The dual luciferase reporter assays demonstrated that miR-19b-3p inhibitor influenced the luciferase activity of luciferase reporter vectors containing WT or MUT 3’UTR of RBMS1. (g, h) RBMS1 knockdown plasmids were added to the basis of miR-19b-3p inhibitor transfection in HepG2 and Hep3B cells. The ROS and MDA level were measured as indicated treatments. (i) Proliferation of HepG2 and Hep3B cells as indicated treatments was evaluated by colony formation assay. (j) RBMS1, GPX4, and 4HNE expression in HepG2 and Hep3B as indicated treatments was evaluated by western blotting. Data are denoted as mean ± SD from three independent experiments.

Article Snippet: Blocking the sections in PBS with 5% BSA for 25 min at room temperature and then incubating the sections with antibodies specific for RBMS1 (1:100, Cat#11061–2-AP, Proteintech), GPX4 (1:200, Cat#A1933, ABclonal), 4HNE (1:100, Cat#MBS808701), and Ki67 (1:100, Cat#16667, Abcam) overnight.

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Luciferase, Plasmid Preparation, Mutagenesis, Binding Assay, Activity Assay, Knockdown, Transfection, Colony Assay

Journal: Epigenetics

Article Title: Suppressing circIDE/miR-19b-3p/RBMS1 axis exhibits promoting-tumour activity through upregulating GPX4 to diminish ferroptosis in hepatocellular carcinoma

doi: 10.1080/15592294.2023.2192438

Figure Lengend Snippet: CircIDE enhances ferroptosis and attenuates proliferation of HCC cells via miR-19b-3p/RBMS11 axis. (a-e) After circIDE overexpression, HepG2 and Hep3B cells were transfected with miR-19b-3p mimic or RBMS1 knockdown plasmid, respectively. (a, b) Western blotting analysis of RBMS1, GPX4, and 4HNE expression in HepG2 and Hep3B as indicated treatments. (c, d) the assessment of ROS and MDA level in HepG2 and Hep3B cells as indicated treatments. (e) Proliferation of HepG2 and Hep3B cells as indicated treatments was evaluated by EdU staining. Scale bar, 20 µm. Data are denoted as mean ± SD from three independent experiments.

Article Snippet: Blocking the sections in PBS with 5% BSA for 25 min at room temperature and then incubating the sections with antibodies specific for RBMS1 (1:100, Cat#11061–2-AP, Proteintech), GPX4 (1:200, Cat#A1933, ABclonal), 4HNE (1:100, Cat#MBS808701), and Ki67 (1:100, Cat#16667, Abcam) overnight.

Techniques: Over Expression, Transfection, Knockdown, Plasmid Preparation, Western Blot, Expressing, Staining

Journal: Epigenetics

Article Title: Suppressing circIDE/miR-19b-3p/RBMS1 axis exhibits promoting-tumour activity through upregulating GPX4 to diminish ferroptosis in hepatocellular carcinoma

doi: 10.1080/15592294.2023.2192438

Figure Lengend Snippet: GPX4 overexpression restores circIDE induced inhibition of tumor growth. (a, b) RT-qPCR analysis of circIDE and GPX4 expression of circIDE overexpression of Hepa 1–6 cells with or without GPX4 overexpression, compared to vector control. (c) Tumor growth was monitored by Xenogen IVIS 200 imaging system. (d) Representative IHC staining and corresponding statistics for RBMS1, GPX4, 4HNE and Ki67 expression in the xenografts tumors. Scale bars, 20 µm. Data are denoted as mean ± SD from three independent experiments.

Article Snippet: Blocking the sections in PBS with 5% BSA for 25 min at room temperature and then incubating the sections with antibodies specific for RBMS1 (1:100, Cat#11061–2-AP, Proteintech), GPX4 (1:200, Cat#A1933, ABclonal), 4HNE (1:100, Cat#MBS808701), and Ki67 (1:100, Cat#16667, Abcam) overnight.

Techniques: Over Expression, Inhibition, Quantitative RT-PCR, Expressing, Plasmid Preparation, Control, Imaging, Immunohistochemistry

Journal: Marine Drugs

Article Title: A New Bioassay Platform Design for the Discovery of Small Molecules with Anticancer Immunotherapeutic Activity

doi: 10.3390/md18120604

Figure Lengend Snippet: Tumor cell lines characteristics.

Article Snippet: Among the tumor cell lines: CALU-1, CALU-3, HCC827, MALME-3M, A375, A2058 were purchased from American Type Culture Collection (ATCC); the 3 lines of multiple myeloma, KMS-12, RPMI 8226, JJN-3 were purchased form the German Collection of Microorganisms and Cell Cultures (DSMZ).

Techniques: Clinical Proteomics